906-P: The Association of British Clinical Diabetologists Audit of Freestyle Libre (FSL) in Diabetes in United Kingdom: Determinants of Time-in-Target Range
Abstract
Objective: Time in range (TIR) is a novel measure of glucose control endorsed by an international consensus group. TIR describes the percentage of TIR (3.9-10mmol/l), time above range (TAR >10mmol/l) and time below range (TBR, <3.9mmol/l) over a given time period. Given the increased use of FreeStyle Libre (FSL) in the UK we were keen to explore the glucose ranges commonly reported in routine clinical practice.
Methods: The ABCD UK FreeStyle Libre audit invited clinicians to submit routine clinical data from FSL users to a secure web-based tool. Data from 101 UK hospitals were analysed using R3.5.0. Linear regression analysis was used to compare the baseline predictors of TIR . TIR was categorised as internationally accepted (3.9-10mmol/l) or individualised (any range other than 3.0-10mmol/l).
Results: Data were available for 10,370 FSL users; age 38 (±18.7) years, 54% female, diabetes duration 16 (±49) years, and BMI of 25.2 (±16.5) kg/m2. Follow-up HbA1c and TIR data was available for 2191 patients. Of those with both follow-up HbA1c and TIR data, in only 343 (15%) cases did clinicians report on the internationally accepted TIR (3.9-10mmol/l), with a median TIR of 43% (27%-56%). Taking both international and individualised TIR together, 221 (10%) had ≥70% TIR, 822 (37%) ≥50% TIR and 1372 (62%) <50% TIR over 14 days. On multivariate regression analysis baseline age (beta=0.13 P<0.0001, number of FSL scans per day (beta= 0.22, P<0.0001) and baseline HbA1c (beta=-0.45, P<0.0001) were associated with higher TIR. The internationally accepted median TBR (<3.9mmol/l) was 6% (3-11) in this cohort.
Conclusion: This population-based study of FSL users demonstrates a limited uptake of the internationally recommended TIR of 3.9-10mmol/l. There is a need for greater awareness of the international recommendations for TIR measures; only a small proportion of people with type 1 diabetes achieve their goals; the number of scans per day predicts greater TIR.
Disclosure E.G. Wilmot: Advisory Panel; Self; Abbott, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic. Speaker’s Bureau; Self; Abbott, Eli Lilly and Company, Insulet Corporation, Novo Nordisk Inc., Sanofi. H. Deshmukh: None. J. Patmore: None. T. Sathyapalan: Research Support; Self; Amgen, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S. Other Relationship; Self; Ipsen Biopharmaceuticals. C. Walton: Speaker’s Bureau; Spouse/Partner; Celgene, LEO Pharma, Novartis Pharmaceuticals Corporation. R. Herring: None. R.E. Ryder: Consultant; Self; GI Dynamics Inc. Other Relationship; Self; Novo Nordisk A/S.
- © 2020 by the American Diabetes Association
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
In this Issue
